AbSci (ABSI) AI Stock Analysis

• Market Cap: $349.51M
• Dividend Yield: N/A
• Average Volume (3M): 3.73M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.54
• Revenue Growth: -9.95%
• EPS Growth: 20.78%
• Country: US
• Employees: 156
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 127,559,350
• 10 Day Avg. Volume: 3,406,415
• 30 Day Avg. Volume: 3,727,165
• PEG Ratio: -2.77
• Price to Book (P/B): 1.61
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.27
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 17.20
• Enterprise Value/Gross Profit: -56.04
• Enterprise Value/Ebitda: -0.84
• 1Y Price Target: $9.17
• Price Target Upside: 218.40% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 50 Neutral
• Price Target: $3.00 ▲(4.17%Upside)

AbSci's overall stock score reflects a challenging financial performance with significant operational inefficiencies. However, recent governance improvements and strategic initiatives in AI-driven drug discovery provide a potential path forward. Technical indicators and valuation show mixed signals, suggesting cautious optimism.

Positive Factors

Financial Performance

Absci's cash & equivalents balance as of the end of 1Q25 was ~$135M, which management estimates provides a runway into 1H27.

Partnerships

Management cited strong potential partnership interest for ABS-101, allowing for a collaboration independent of the TL1A bispecific that Absci is progressing through its early pipeline.

Technology and Innovation

Absci's AI-driven Antibody Design Model could help select antibody variants that are more human-like to mitigate potential downstream issues.

Negative Factors

Revenue

Absci reported 1Q25 revenues of $1.2M, which fell short of the consensus estimate of $2.6M.

Risks

Risks to the Buy rating include potential issues with partnerships, technology, clinical and regulatory challenges, and competition.

AbSci Business Overview & Revenue Model

Company Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

How the Company Makes Money

AbSci generates revenue primarily through collaborations and partnerships with pharmaceutical and biotechnology companies. These partnerships typically involve research and development agreements where AbSci provides its expertise and technology to help partners discover, design, and optimize protein-based drugs. The company earns money through upfront payments, milestone payments, and royalties based on the success and commercialization of the therapeutics developed using its platform. Additionally, AbSci may offer contract services for specific research and development projects, contributing further to its revenue streams.

AbSci Financial Statement Overview

Summary

AbSci is struggling with profitability and cash flow generation, as evidenced by negative margins and cash flow metrics. The balance sheet remains relatively stable, with a solid equity base and low leverage, but operational inefficiencies and growth challenges present substantial risks that need to be addressed to improve financial health.

Income Statement

The income statement reveals persistent revenue stagnation and consistent net losses. The Gross Profit Margin and Net Profit Margin are negative, highlighting ongoing operational challenges. Revenue growth remains unstable with a decline in recent periods, while negative EBIT and EBITDA margins indicate significant operational inefficiencies.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio, indicating financial leverage is not a major concern. However, the continued net losses impede returns, as evidenced by the negative ROE. The equity ratio is relatively stable but has been decreasing, reflecting potential asset allocation challenges.

Cash Flow

Operating Cash Flow remains negative, reflecting ongoing cash burn, while Free Cash Flow also faces significant challenges. The company’s cash flow from operations compared to net income shows issues in converting income into cash, despite positive financing activities in recent periods providing liquidity support.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.53M	5.72M	5.75M	4.78M	4.78M
Gross Profit	-8.86M	-41.85M	-7.29M	-1.87M	-6.67M
EBITDA	-89.08M	-95.46M	-91.36M	-99.77M	-12.59M
Net Income	-103.11M	-110.57M	-104.90M	-100.96M	-14.57M
Balance Sheet
Total Assets	213.61M	217.30M	321.01M	426.19M	88.57M
Cash, Cash Equivalents and Short-Term Investments	112.42M	97.66M	164.43M	252.57M	69.87M
Total Debt	10.11M	15.96M	22.98M	20.01M	14.50M
Total Liabilities	34.48M	41.12M	46.59M	60.09M	178.00M
Stockholders Equity	179.13M	176.18M	274.41M	366.11M	-89.43M
Cash Flow
Free Cash Flow	-72.81M	-65.50M	-97.51M	-98.64M	-13.15M
Operating Cash Flow	-72.40M	-64.64M	-81.34M	-60.60M	-10.97M
Investing Cash Flow	-41.58M	81.94M	-126.98M	-67.38M	-2.17M
Financing Cash Flow	82.53M	-4.48M	5.24M	336.19M	70.97M

AbSci Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.88
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABSI, the sentiment is Positive. The current price of 2.88 is above the 20-day moving average (MA) of 2.71, above the 50-day MA of 2.77, and below the 200-day MA of 3.30, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 56.24 is Neutral, neither overbought nor oversold. The STOCH value of 50.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABSI.

AbSci Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	78 Outperform	$641.51M	15.13	20.50%	―	2333.50%	―
UPB	64 Neutral	$587.43M	―		―	―	―
ZVRA	63 Neutral	$699.35M	―	-204.78%	―	44.92%	-40.06%
ABSI	50 Neutral	$349.51M	―	-48.98%	―	-9.95%	20.78%
Sector *	46 Neutral	C$197.02M	-3.33	-23.14%	2.65%	20.75%	-0.36%
OMER	40 Underperform	$211.52M	―	87.26%	―	―	-43.76%
SANA	33 Underperform	$976.65M	―	-71.44%	―	―	19.94%

AbSci Corporate Events

AbSci Appoints Mary Szela to Board of Directors

On July 7, 2025, Absci Corporation appointed Mary Szela to its Board of Directors, expanding the board to seven members. Ms. Szela, who is also the CEO, President, and Director of Trisalus Life Sciences, will serve as a Class III director until the 2027 annual meeting. She was granted an option to purchase 178,400 shares of the company’s stock, which will vest monthly over three years, and will receive an annual $40,000 cash retainer.

The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.

Absci Elects New Board Members at Annual Meeting

On June 11, 2025, Absci Corporation held its Annual Meeting of Stockholders, where shareholders voted to elect Frans van Houten and Karen McGinnis as Class I board members and ratified Ernst & Young LLP as the independent accounting firm for 2025. The approval of these proposals is expected to strengthen Absci’s governance and financial oversight, potentially enhancing its industry positioning and stakeholder confidence.

The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.

Absci Initiates First Human Study for ABS-101

On May 13, 2025, Absci Corporation announced the initiation of its first-in-human study for ABS-101, marking its transition to a clinical-stage biotech company. The company also shared promising preclinical data for ABS-201, indicating potential for a more effective treatment for androgenetic alopecia. Financially, Absci reported a net loss of $26.3 million for Q1 2025, with cash reserves expected to fund operations into the first half of 2027. The company’s strategic focus remains on advancing its internal pipeline and expanding partnerships, with anticipated new collaborations in 2025.

The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.